[
  {
    "topic": "pharmacology",
    "question": "The suffix '-ximab' indicates that a monoclonal antibody is:",
    "options": [
      "Conjugated to a toxin",
      "Humanized",
      "Fully murine",
      "Chimeric"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a mechanism of action for trastuzumab?",
    "options": [
      "Direct DNA intercalation",
      "Inhibition of HER2/neu dimerization",
      "Complement-dependent cytotoxicity (CDC)",
      "ADCC (antibody-dependent cellular cytotoxicity)"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which mechanism is LEAST likely involved in monoclonal antibody (moAb) cancer cell killing?",
    "options": [
      "Direct inhibition of DNA replication",
      "Complement-dependent cytotoxicity (CDC)",
      "Antibody-dependent cellular cytotoxicity (ADCC)",
      "Induction of apoptosis"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which monoclonal antibody is used intravitreally for age-related macular degeneration?",
    "options": [
      "Rituximab",
      "Bevacizumab",
      "Alemtuzumab",
      "Cetuximab"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Cetuximab (Erbitux) binds to which receptor?",
    "options": [
      "VEGFR",
      "HER1 (EGFR)",
      "CD33",
      "HER2/neu"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Gemtuzumab ozogamicin (Mylotarg) is a conjugate of an antibody and which cytotoxic agent?",
    "options": [
      "Doxorubicin",
      "Paclitaxel",
      "Methotrexate",
      "Calicheamicin"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a toxicity of gemtuzumab ozogamicin?",
    "options": [
      "Hepatotoxicity",
      "GI perforation",
      "Hypertension",
      "Cardiomyopathy"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which toxicity is unique to alemtuzumab compared to other monoclonal antibodies?",
    "options": [
      "Infusion reactions",
      "Hypertension",
      "Cardiomyopathy",
      "Pancytopenia"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "The half-life of rituximab is approximately:",
    "options": [
      "4-5 days",
      "3-4 weeks",
      "2 weeks",
      "3 days"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a clearance mechanism for monoclonal antibodies?",
    "options": [
      "Target-mediated clearance (drug-antigen complex)",
      "Renal excretion",
      "Pinocytosis",
      "Lysosomal degradation"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a bispecific monoclonal antibody (still in trials)?",
    "options": [
      "Trastuzumab",
      "Bevacizumab",
      "Rituximab",
      "Blinatumomab"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "What is the primary structural difference between humanized (suffix '-zumab') and chimeric (suffix '-ximab') monoclonal antibodies?",
    "options": [
      "Humanized antibodies are entirely non-human; chimeric antibodies are fully human.",
      "Chimeric antibodies target multiple epitopes; humanized antibodies target one.",
      "Humanized antibodies are conjugated to toxins; chimeric antibodies are naked.",
      "Humanized antibodies have near-human amino acid sequences; chimeric antibodies contain larger non-human protein stretches."
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which monoclonal antibody is cleared faster in males and patients with high tumor burden?",
    "options": [
      "Alemtuzumab",
      "Rituximab",
      "Bevacizumab",
      "Trastuzumab"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT a reported toxicity of trastuzumab?",
    "options": [
      "Acute infusion reactions",
      "Cardiomyopathy",
      "Fatigue",
      "Veno-occlusive disease"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a severe toxicity of rituximab?",
    "options": [
      "Osteoporosis",
      "GI perforation",
      "Hepatotoxicity",
      "Late-onset neutropenia"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which monoclonal antibody is approved for pemphigus vulgaris?",
    "options": [
      "Bevacizumab",
      "Rituximab",
      "Cetuximab",
      "Trastuzumab"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Alemtuzumab (Campath) targets which antigen?",
    "options": [
      "CD33",
      "CD52",
      "CD20",
      "HER1"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Rituximab (Rituxan) is a chimeric antibody targeting:",
    "options": [
      "HER2/neu",
      "EGFR",
      "VEGF",
      "CD20"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which monoclonal antibody is associated with severe skin toxicities?",
    "options": [
      "Gemtuzumab ozogamicin",
      "Rituximab",
      "Bevacizumab",
      "Cetuximab"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Bevacizumab (Avastin) targets which of the following?",
    "options": [
      "HER2/neu receptor",
      "Vascular endothelial growth factor (VEGF)",
      "EGFR (HER1)",
      "CD20 on B cells"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which monoclonal antibody is associated with the risk of veno-occlusive disease?",
    "options": [
      "Trastuzumab",
      "Rituximab",
      "Gemtuzumab ozogamicin",
      "Bevacizumab"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which cancer type is gemtuzumab ozogamicin used to treat?",
    "options": [
      "CD33-positive AML",
      "Non-small cell lung cancer",
      "Colorectal cancer",
      "HER2-positive breast cancer"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a major toxicity of bevacizumab linked to its anti-VEGF action?",
    "options": [
      "Hypertension",
      "Peripheral neuropathy",
      "Cardiomyopathy",
      "Bone marrow suppression"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Trastuzumab (Herceptin) is indicated for cancers that overexpress:",
    "options": [
      "HER2/neu",
      "VEGFR",
      "CD52",
      "CD33"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a chimeric antibody?",
    "options": [
      "Alemtuzumab",
      "Bevacizumab",
      "Cetuximab",
      "Trastuzumab"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a common side effect of cetuximab?",
    "options": [
      "Bone demineralization",
      "Cardiomyopathy",
      "Acneiform rash",
      "Veno-occlusive disease"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a naked monoclonal antibody?",
    "options": [
      "Ibritumomab tiuxetan (radioactive conjugate)",
      "Trastuzumab",
      "Gemtuzumab ozogamicin",
      "90Y-ibritumomab tiuxetan"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "The bioavailability of monoclonal antibodies administered intravenously is typically:",
    "options": [
      "Variable",
      "100%",
      "75%",
      "50%"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which condition is alemtuzumab NOT approved to treat?",
    "options": [
      "Colorectal cancer",
      "Multiple sclerosis",
      "Non-Hodgkin\u2019s lymphoma",
      "B-cell chronic lymphocytic leukemia (B-CLL)"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Which monoclonal antibody is used in Wegener\u2019s granulomatosis?",
    "options": [
      "Cetuximab",
      "Bevacizumab",
      "Alemtuzumab",
      "Rituximab"
    ],
    "correct_option": 3
  }
]